Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls Sells 5,937 Shares

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls sold 5,937 shares of the business’s stock in a transaction on Friday, March 28th. The stock was sold at an average price of $71.55, for a total value of $424,792.35. Following the completion of the transaction, the director now directly owns 6,500 shares in the company, valued at approximately $465,075. This represents a 47.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Soleno Therapeutics Trading Down 0.8 %

Shares of NASDAQ SLNO traded down $0.54 during midday trading on Monday, hitting $71.45. The company’s stock had a trading volume of 4,004,984 shares, compared to its average volume of 649,585. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of -21.52 and a beta of -1.70. The stock has a fifty day moving average price of $49.44 and a 200 day moving average price of $50.23. Soleno Therapeutics, Inc. has a one year low of $36.61 and a one year high of $73.97.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41). On average, equities research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SLNO shares. Cantor Fitzgerald lifted their target price on Soleno Therapeutics from $67.00 to $123.00 and gave the stock an “overweight” rating in a research note on Thursday. HC Wainwright lifted their price objective on shares of Soleno Therapeutics from $70.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday. Laidlaw increased their target price on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday. Guggenheim restated a “buy” rating and set a $81.00 price target (up previously from $70.00) on shares of Soleno Therapeutics in a research note on Friday. Finally, Lifesci Capital upgraded Soleno Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 4th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $98.86.

Institutional Trading of Soleno Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AlphaQuest LLC boosted its stake in Soleno Therapeutics by 1,154.4% in the 4th quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after purchasing an additional 658 shares during the period. US Bancorp DE purchased a new stake in shares of Soleno Therapeutics in the fourth quarter worth about $34,000. Avanza Fonder AB bought a new position in shares of Soleno Therapeutics in the fourth quarter valued at approximately $76,000. Springhill Fund Asset Management HK Co Ltd purchased a new position in Soleno Therapeutics during the fourth quarter valued at approximately $81,000. Finally, Avior Wealth Management LLC purchased a new position in Soleno Therapeutics during the fourth quarter valued at approximately $89,000. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.